A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis

2022 ◽  
Author(s):  
Wataru Izumo ◽  
Ryota Higuchi ◽  
Toru Furukawa ◽  
Takehisa Yazawa ◽  
Shuichiro Uemura ◽  
...  
Keyword(s):  
Portal Vein ◽  
Cell Carcinoma ◽  
Preoperative Chemotherapy ◽  
Acinar Cell ◽  
Complete Response ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Portal Vein Tumor Thrombosis ◽  
Tumor Thrombosis ◽  
Pancreatic Acinar Cell Carcinoma

scholarly journals Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma

2015 ◽  
Vol 8 (3) ◽  
pp. 447-450 ◽  
Author(s):  
Anne Ploquin ◽  
Capucine Baldini ◽  
Perrine Vuagnat ◽  
Samira Makhloufi ◽  
Christophe Desauw ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Case Reports ◽  
Brca2 Mutation ◽  
Complete Response ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Rare Entity ◽  
Pancreatic Acinar Cell Carcinoma ◽  
Multiple Metastases

Pancreatic acinar cell carcinoma (ACC) is a rare entity. Herein we present the case of a 50-year-old male patient with an unlimited mass on the pancreatic corpus and tail with peripancreatic effusion and multiple metastases in the liver and spleen. A liver biopsy showed a pancreatic ACC. The patient received 9 cycles of gemcitabine plus oxaliplatin (GEMOX regimen), which had to be stopped because of a persistent grade 2 neuropathy. A CT scan showed complete response after 14 years. At the age of 61 years, a localized prostatic cancer was diagnosed, treated by prostatectomy. The patient carried a BRCA2 mutation. None of the precedent case reports describe a chemosensibility to the GEMOX regimen. In spite of the lack of study in these patients, chemotherapy with oxaliplatin seems to be the most effective. Long survival can be expected.

Pancreatic acinar cell carcinoma with extensive tumor embolism at the trunk of portal vein and pancreatic intraductal infiltration

2017 ◽  
Vol 10 (6) ◽  
pp. 546-550 ◽  
Author(s):  
Akihiko Kida ◽  
Koichiro Matsuda ◽  
Kai Takegoshi ◽  
Mitsuru Matsuda ◽  
Akito Sakai ◽  
...  
Keyword(s):  
Portal Vein ◽  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Tumor Embolism ◽  
Pancreatic Acinar Cell Carcinoma

Cushing’s Syndrome in a Child with Pancreatic Acinar Cell Carcinoma

2007 ◽  
Vol 18 (2) ◽  
pp. 95-102 ◽  
Author(s):  
György Illyés ◽  
Andrea Luczay ◽  
Gábor Benyó ◽  
Attila Kálmán ◽  
Katalin Borka ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Cushing’S Syndrome ◽  
Acinar Cell Carcinoma ◽  
Cushing's Syndrome ◽  
Pancreatic Acinar Cell ◽  
Pancreatic Acinar Cell Carcinoma

The CT findings of pancreatic acinar cell carcinoma in five cases

2013 ◽  
Vol 37 (2) ◽  
pp. 302-307 ◽  
Author(s):  
Kefu Liu ◽  
Weijun Peng ◽  
Zhengrong Zhou
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Ct Findings ◽  
Pancreatic Acinar Cell Carcinoma

scholarly journals Alpha-fetoprotein-producing Pancreatic Acinar Cell Carcinoma

2007 ◽  
Vol 106 (8) ◽  
pp. 669-672 ◽  
Author(s):  
Yang-Chao Lin ◽  
Po-Huang Lee ◽  
Yu-Tung Yao ◽  
Jong-Kai Hsiao ◽  
Jin-Chuan Sheu ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Alpha Fetoprotein ◽  
Pancreatic Acinar Cell Carcinoma

Pancreatic acinar cell carcinoma in familial adenomatous polyposis

1996 ◽  
Vol 3 (1) ◽  
pp. 71-73 ◽  
Author(s):  
Takashi Ohsato ◽  
Ryuichi Mibu ◽  
Eishi Nagai ◽  
Hiroshi Satoh ◽  
Mitsuo Iida ◽  
...  
Keyword(s):  
Familial Adenomatous Polyposis ◽  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Adenomatous Polyposis ◽  
Pancreatic Acinar Cell Carcinoma

scholarly journals Primary unresectable pancreatic acinar cell carcinoma which became resectable after S-1 and Oxaliplatin treatment

Suizo ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 270-278
Author(s):  
Taro MASHIKO ◽  
Kohei TAJIMA ◽  
Naoki YAZAWA ◽  
Yoshihito MASUOKA ◽  
Toshio NAKAGOHRI
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Oxaliplatin Treatment ◽  
Pancreatic Acinar Cell Carcinoma

scholarly journals Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literatures

2021 ◽  
Author(s):  
Jianying Xu ◽  
Wenlong Guan ◽  
Shixun Lu ◽  
Xiaoli Wei ◽  
Wenjie Shi ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Acinar Cell ◽  
Maintenance Treatment ◽  
Objective Response ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Cancer Center ◽  
Pancreatic Acinar Cell Carcinoma ◽  
Line Chemotherapy

Abstract Background: Pancreatic acinar cell carcinoma (PACC) is rare and its appropriate treatment remains unknown dued to limited and selection-biased dataMethods: The data on clinicopathologic characteristics, molecular alteration, treatment and survival of patients diagnosed as PACC in Sun Yat-sen university cancer center from 2005 to 2020 were collected. We explored the optimal treatment by co-analyzing our results and published literatures.Results: 22 PACC patients were enrolled. 8/17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n=3) had better mDFS than those with gemcitabine-based regimen (n=5) (unreached vs. 27 months). 8 metastatic patients received 1st-line chemotherapy. 4/5 patients with FOLFIRINOX regimen achieved partial response (PR) and 3 patients with AG (albumin paclitaxel+gemcitabine) regimen got progressive disease (PD). 4 patients received 2nd-line chemotherapy. 2 patients with FOLFIRINOX regimen achieved PR while 2 patients with AG regimen got PD. One patient who had responded to 1st-line FOLFIRINOX regimen received Olaparib as maintenance treatment for 5 months with good tolerance. 31 published literatures and a total of 86 cases were included in the co-analysis. Objective response rate of 1st-line fluoropyrimidine-based regimen (n=47) was higher than that of gemcitabine-based regimen (n=39) (59.6% vs.15.3%, P<0.001). 8/11 patients treated with FOLFIRINOX regimen achieved PR. Conclusions: The benefit of adjuvant chemotherapy remained unclear; however, fluoropyrimidine-based chemotherapy deserves attention. For metastatic patients, fluorouracil-based regimen such as FOLFIRINOX is preferred, and maintenance treatment of PARP inhibitors after effective platinum-containing treatment for BRAC mutation patients is worthy of exploration.

Sign in / Sign up

Export Citation Format

Share Document